How to Use Pemvidutide
Complete guide to Pemvidutide dosing, administration, timing, and protocol recommendations.
Quick Overview
Pemvidutide is Altimmune's once-weekly GLP-1/glucagon dual agonist, now being developed mainly for MASH (fatty liver disease with inflammation, formerly called NASH). It cleared fat out of the liver fast in trials and earned FDA Breakthrough Therapy designation, and its phase 3 trial (PERFORMA) started in August 2026. It also produced decent weight loss in an obesity trial, but it is not approved anywhere and its biggest phase 2 MASH trial missed on the fibrosis endpoint at 24 weeks.
Dosing Guidelines
Common Dose
1.2-1.8 mg once weekly (MASH trial doses)
Frequency
Once weekly
Dose Range
1.2-2.4 mg weekly in trials
Note: These are phase 2 and phase 3 trial doses, not recommendations. Phase 3 titrates monthly from 1.2 mg to reach the trial dose. No dose has been approved for any use.
Administration Method
Subcutaneous injection once weekly
Best Time to Take
Same day each week
Long-acting weekly peptide, so steady weekly timing keeps levels consistent. Time of day is not specified in the trial reports.
Protocol Duration
24-48 weeks in completed trials; phase 3 runs 52 weeks for the biopsy endpoint and years for outcomes
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea
- •Vomiting
- •Diarrhea
- •Mostly mild to moderate GI effects during titration
- •Possible effects on blood sugar from glucagon activity (watch in diabetes)
Frequently Asked Questions
What is the recommended dose for Pemvidutide?
1.2-1.8 mg once weekly (MASH trial doses)
How do you administer Pemvidutide?
Subcutaneous injection once weekly
When is the best time to take Pemvidutide?
Same day each week
How long should you use Pemvidutide?
24-48 weeks in completed trials; phase 3 runs 52 weeks for the biopsy endpoint and years for outcomes
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.